Developing an Anti-Xa-Based Anticoagulation Protocol for Patients with Percutaneous Ventricular Assist Devices.

Area of Science:

• Cardiology
• Biomedical Engineering
• Pharmacology

Background:

• Anticoagulation management for patients with temporary percutaneous ventricular assist devices (pVADs) lacks standardization due to inherent complexities.
• Current practices vary, necessitating an evaluation to identify optimal anticoagulation strategies.

Purpose of the Study:

• To retrospectively analyze anticoagulation practices in pVAD recipients at a single center.
• To identify an optimal anticoagulation strategy and protocol for pVAD patients.

Main Methods:

• Retrospective analysis of patients with temporary pVADs, categorized by device type (CentriMag/TandemHeart vs. Impella).
• Subgroup analysis within the CentriMag/TandemHeart cohort based on anticoagulation monitoring (aPTT vs. anti-Xa).
• Evaluation of bleeding and thrombotic complications in each cohort.

Main Results:

• In the CentriMag/TandemHeart cohort monitored with anti-Xa, one patient experienced device thrombosis and major bleeding, while another had major bleeding.
• In the Impella cohort, seven major bleeds occurred in three patients, with no thrombotic events.
• Distinct differences in outcomes were observed between device types and monitoring strategies.

Conclusions:

• Development of two distinct protocols to guide anticoagulation adjustments based on device type and observed outcomes.
• Emphasizes the complexity of pVAD anticoagulation, requiring individualized management.
• Recommends integrating coagulation parameters with hemodynamic and clinical status for optimal anticoagulation goals.